Related Experiment Videos
Cefepime
1Pharmacy Service, Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX 78284.
Abstract:
Cefepime is a potent, broad-spectrum, fourth-generation cephalosporin with enhanced activity against most gram-positive aerobic bacterial pathogens and many gram-negative aerobic bacteria that are resistant to other cephalosporins. The drug's zwitterionic structure contributes to more rapid penetration of gram-negative bacterial cell membranes, and its low affinity for most type I beta-lactamases leads to significantly reduced enzymatic degradation compared with other cephalosporins. Cefepime has a good toxicity profile, with minor gastrointestinal and central nervous system symptoms being most prevalent. At dosages ranging from 1-2 g every 8-12 hours, it is an alternative option for infections of the lower respiratory tract, urinary tract, and skin and skin structures, as well as febrile episodes in neutropenic patients with cancer, and bacteremia or septicemia in critically ill patients.
Insights
Cefepime, a fourth-generation cephalosporin antibiotic, offers broad-spectrum activity against resistant bacteria. Its unique structure enhances bacterial cell penetration and reduces degradation, making it an effective treatment option.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Cefepime is a fourth-generation cephalosporin antibiotic.
- It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria.
- It demonstrates enhanced efficacy against bacteria resistant to other cephalosporins.
Purpose of the Study:
- To review the properties and clinical applications of cefepime.
- To highlight its advantages over other cephalosporins.
- To discuss its safety and efficacy in various infections.
Main Methods:
- Literature review of cefepime's pharmacokinetic and pharmacodynamic properties.
- Analysis of clinical trial data regarding efficacy and safety.
- Comparison with other cephalosporin antibiotics.
Main Results:
- Cefepime's zwitterionic structure facilitates rapid penetration of Gram-negative bacterial membranes.
- Low affinity for type I beta-lactamases results in reduced enzymatic degradation.
- Clinical studies support its effectiveness in treating lower respiratory tract, urinary tract, and skin infections, as well as febrile neutropenia, bacteremia, and septicemia.
Conclusions:
- Cefepime is a potent antibiotic with a favorable safety profile.
- It is a valuable therapeutic option for serious bacterial infections, including those caused by resistant pathogens.
- Its pharmacokinetic and pharmacodynamic properties contribute to its clinical utility.